Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature

Thrombosis Research

Volumn 129, Issue 3, 2012, Pages 392-400

  Becattini, Cecilia ^a   Vedovati, Maria Cristina ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

anticoagulant therapy; anticoagulants; antithrombotic therapy; direct thrombin inhibitors; factor Xa inhibitors

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; MORTALITY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84857785996     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.014     Document Type: Review

References (50)

1. W. Geerts, D. Bergquist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism. American college of chest Physicians Evidence-Based Clinical Practice guidelines (8th Edition) Chest 133 2008 381S 453S (Pubitemid 351894916)
2. D.E. Singer, G.W. Albers, J.E. Dalen, M.C. Fang, A.S. Go, and J.L. Halperin Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 546S 592S (Pubitemid 351892972)
3. S.M. Bates, I.A. Greer, I. Pabinger, S. Sofaer, J. Hirsh, and American College of Chest Physicians Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 844S 886S (Pubitemid 351892978)
4. A.G. Turpie, M.R. Lassen, B.I. Eriksson, M. Gent, S.D. Berkowitz, and F. Misselwitz Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
5. J. Huang, Y. Cao, C. Liao, L. Wu, and F. Gao Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials Thromb Haemost 105 2011 245 253
6. S.E. Wolowacz, N.S. Roskell, J.M. Plumb, J.A. Caprini, and B.I. Eriksson Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis Thromb Haemost 101 2009 77 85
7. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
8. B. Furie, and B.C. Furie Molecular and cellular biology of blood coagulation N Engl J Med 326 1992 800 806
9. K. Mann, S. Butenas, and K. Brummel The dynamics of thrombin formation Arterioscler Thromb Vasc Biol 23 2003 17 25 (Pubitemid 36091621)
10. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodinamics and pharmacocinetics of BAY 59-7939, an oral, direct, Factor Xa inhibitor after multiple dosing in healty male subjects Eur J Clin Pharmacol 61 2005 873 880 (Pubitemid 41803696)
11. V. Seagroatt, H.S. Tan, and M. Goldcre Elective total hip replacement: incidence, emergency readmission rate and postoperative mortality BMJ 303 1991 1431 1435
12. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
13. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
14. The RE-MOBILIZE writing Committee Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regime for prevention of Venous Thromboembolism after Knee Arthroplasty Surgery J Arthroplasty 24 1 2009
15. R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, and C.W. Francis Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thromb Res 126 2010 175 182
16. B.I. Eriksson, O.E. Dahl, M.H. Huo, A.A. Kurth, S. Hantel, and K. Hermansson Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
17. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
18. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
19. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
20. S.Z. Goldhaber, A. Leizorovicz, A.K. Kakkar, S.K. Haas, G. Merli, and R.M. Knabb Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients N Engl J Med 365 2011 2167 2177
21. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
22. M.R. Lassen, W. Ageno, J.R. Borris LC Lieberman, N. Rosencher, T.J. Bandel, and F. Misselwitz Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty N Engl J Med 358 26 2008
23. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 35 39
24. A. Turpie, M. Lassen, B. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial Lancet 373 2009 1673 1680
25. Cohen AT for the MAGELLAN Investigators. Rivaroxaban compares favorably with enoxaparin in preventing venous thromboembolism in acutely ill patients without showing a net clinical benefit. ACC Congress 2011-04-05, New Orleans, USA.
26. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai Randomized, double-blind, multidose efficacy, safety and bio -marker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty Blood 112 2008 34
27. G. Raskob, A. Cohen, B. Eriksson, A. Macdonald, D. Puskas, and M. Shi Randomized double-blind multi-dose trial of the oral factor Xa inhibitor DU-176b versus LMW heparin (dalteparin) for prevention of venous thromboembolism after total hip replacement Eur Heart J 29 2008 609 (abstract supplement)
28. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
29. S. Schulman, D. Baanstra, and H. Eriksson Dabigatran versus placebo for extended manteinance therapy of venous thromboembolism J Thromb Haemost 9 s2 2011 037
30. S. Schulman, H. Eriksson, S.Z. Goldhaber, A.K. Kakkar, C. Kearon, and A.M. Kvamme Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism J Thromb Haemost 9 s2 2011 731
31. Botticelli Investigators Writing Committe, H. Buller, D. Deitchman, M. Prins, and A. Segers Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J Thromb Haemost 2008 1313 1318 (Pubitemid 352016310)
32. EINSTEIN Investigators R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, and H. Decousus Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
33. Y. Miyasaka, M.E. Barnes, B.J. Gersh, S.S. Cha, K.R. Bailey, and W.P. Abhayaratna Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125 (Pubitemid 44420743)
34. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
35. S.J. Connolly, A. Laupacis, M. Gent, R.S. Roberts, J. Cairns, and C. Joyner Canadian Atrial Fibrillation Anticoagulation (CAFA) study J Am Coll Cardiol 18 1991 349 355
36. European Atrial Fibrillation Trial Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke Lancet 342 1993 1255 1262
37. Atrial Fibrillation Investigators The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials Arch Intern Med 157 1997 1237 1240
38. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis Ann Intern Med 131 1999 492 501 (Pubitemid 29482392)
39. M. Marietta, P. Pedrazzi, M. Girardis, and G. Torelli Intracerebral haemorrhage: an often neglected medical emergency Intern Emerg Med 2 2007 38 45
40. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
41. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
42. L. Wallentin, S. Yusuf, M.D. Ezekowitz, M. Alings, M. Flather, and M.G. Franzosi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
43. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, and S. Golitsyn AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
44. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
45. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
46. J.I. Weitz, S.J. Connolly, I. Patel, D. Salazar, S. Rohatagi, and J. Mendell Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 104 2010 633 641
47. M.A. Crowther, and T.E. Warkentin Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents J Thromb Haemost 7 2009 107 110
48. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
49. J.M. Walenga, and C. Adiguzel Drug and dietary interactions of the new and emerging oral anticoagulants Int J Clin Pract 64 2010 956 967
50. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876